Background Neonates, infants, children and adolescents are in a continuous and dynamically changing state of growth and development. Marked differences in the pharmacokinetic and pharmacodynamic behavior of many drugs are reported between the pediatric population and adults due to the maturational changes in physiological parameters during childhood. The lack of maturational pharmacokinetic-pharmacodynamic data directly results in the variation and uncertainty of drug therapy in pediatric clinical practice. The urgent need to improve pediatric drug therapy has been recognized by regulators and public health professionals. This Research Topic will focus on application of model-based evaluation of antimicrobial agents in the pediatric population. Both drug development as well as individualized therapy of antimicrobial agents in this population will be considered for publication.
Goal There has been a growing interest in exploring innovative methodology to optimize pediatric drug development, as well as individualized therapy. In this context, pharmacometrics presents a promising and valuable approach. Pharmacometrics is the science of quantitative pharmacology. In application to pediatrics, it involves primarily developmental pharmacokinetic and pharmacodynamic modeling and simulation, which can combine information from many diverse sources as drug characteristics, developmental clinical pharmacology, physiological changes during childhood, pediatric disease and statistics. In this Research Topic, we would like to highlight the value of model-based drug evaluation of antimicrobial agents in neonates, infants, children, and adolescents.
Scope and Information for Authors: model-based drug development of antimicrobial agents in the pediatric population; model-based individualized antimicrobial therapy in neonates, infants, children, and adolescents.
Type of manuscripts: Original Research; Brief Research Report; Review; Study Protocol.
Topic Editor Johannes N. van den Anker is the Chief Medical Officer at Reveragen Biopharma, as well as holding his positions at academic institutions. The other Topic Editor declares no competing interests with regard to the Research Topic subject.
Background Neonates, infants, children and adolescents are in a continuous and dynamically changing state of growth and development. Marked differences in the pharmacokinetic and pharmacodynamic behavior of many drugs are reported between the pediatric population and adults due to the maturational changes in physiological parameters during childhood. The lack of maturational pharmacokinetic-pharmacodynamic data directly results in the variation and uncertainty of drug therapy in pediatric clinical practice. The urgent need to improve pediatric drug therapy has been recognized by regulators and public health professionals. This Research Topic will focus on application of model-based evaluation of antimicrobial agents in the pediatric population. Both drug development as well as individualized therapy of antimicrobial agents in this population will be considered for publication.
Goal There has been a growing interest in exploring innovative methodology to optimize pediatric drug development, as well as individualized therapy. In this context, pharmacometrics presents a promising and valuable approach. Pharmacometrics is the science of quantitative pharmacology. In application to pediatrics, it involves primarily developmental pharmacokinetic and pharmacodynamic modeling and simulation, which can combine information from many diverse sources as drug characteristics, developmental clinical pharmacology, physiological changes during childhood, pediatric disease and statistics. In this Research Topic, we would like to highlight the value of model-based drug evaluation of antimicrobial agents in neonates, infants, children, and adolescents.
Scope and Information for Authors: model-based drug development of antimicrobial agents in the pediatric population; model-based individualized antimicrobial therapy in neonates, infants, children, and adolescents.
Type of manuscripts: Original Research; Brief Research Report; Review; Study Protocol.
Topic Editor Johannes N. van den Anker is the Chief Medical Officer at Reveragen Biopharma, as well as holding his positions at academic institutions. The other Topic Editor declares no competing interests with regard to the Research Topic subject.
